[go: up one dir, main page]

WO2001034792A3 - Compositions and methods for the diminution or elimination of various cancers - Google Patents

Compositions and methods for the diminution or elimination of various cancers Download PDF

Info

Publication number
WO2001034792A3
WO2001034792A3 PCT/US2000/030869 US0030869W WO0134792A3 WO 2001034792 A3 WO2001034792 A3 WO 2001034792A3 US 0030869 W US0030869 W US 0030869W WO 0134792 A3 WO0134792 A3 WO 0134792A3
Authority
WO
WIPO (PCT)
Prior art keywords
diminution
elimination
compositions
methods
various cancers
Prior art date
Application number
PCT/US2000/030869
Other languages
French (fr)
Other versions
WO2001034792A2 (en
Inventor
Olga Potapova
Myriam Gorospe
Nikki J Holbrook
Original Assignee
Us Health
Olga Potapova
Myriam Gorospe
Nikki J Holbrook
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Olga Potapova, Myriam Gorospe, Nikki J Holbrook filed Critical Us Health
Priority to AU14808/01A priority Critical patent/AU1480801A/en
Publication of WO2001034792A2 publication Critical patent/WO2001034792A2/en
Publication of WO2001034792A3 publication Critical patent/WO2001034792A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the treatment of cancer utilizing Jun Kinase antisense (JNK2AS) mRNA. Additionally, the present invention relates to the screening of reagents that may augment or mimic the effect of JNK2AS treatment for cancer.
PCT/US2000/030869 1999-11-12 2000-11-10 Compositions and methods for the diminution or elimination of various cancers WO2001034792A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU14808/01A AU1480801A (en) 1999-11-12 2000-11-10 Compositions and methods for the diminution or elimination of various cancers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16522499P 1999-11-12 1999-11-12
US60/165,224 1999-11-12

Publications (2)

Publication Number Publication Date
WO2001034792A2 WO2001034792A2 (en) 2001-05-17
WO2001034792A3 true WO2001034792A3 (en) 2001-11-22

Family

ID=22597994

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030869 WO2001034792A2 (en) 1999-11-12 2000-11-10 Compositions and methods for the diminution or elimination of various cancers

Country Status (2)

Country Link
AU (1) AU1480801A (en)
WO (1) WO2001034792A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0716072D0 (en) * 2007-08-17 2007-09-26 Univ York Therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023050A1 (en) * 1993-04-05 1994-10-13 University Of Connecticut Targeted delivery of genes encoding antisense polyribonucleotides
WO1999009214A1 (en) * 1997-08-13 1999-02-25 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions and methods for the modulation of jnk proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023050A1 (en) * 1993-04-05 1994-10-13 University Of Connecticut Targeted delivery of genes encoding antisense polyribonucleotides
WO1999009214A1 (en) * 1997-08-13 1999-02-25 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions and methods for the modulation of jnk proteins

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BOST FREDERIC ET AL: "The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells.", MOLECULAR AND CELLULAR BIOLOGY, vol. 19, no. 3, March 1999 (1999-03-01), pages 1938 - 1949, XP002169471, ISSN: 0270-7306 *
BOST FREDERIC ET AL: "The JUN kinase/stress-activated protein kinase pathway is required for epidermal growth factor stimulation of growth of human A549 lung carcinoma cells.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 52, 26 December 1997 (1997-12-26), pages 33422 - 33429, XP002169470, ISSN: 0021-9258 *
FUCHS SERGE Y ET AL: "JNK targets p53 ubiquitination and degradation in nonstressed cells.", GENES & DEVELOPMENT, vol. 12, no. 17, 1998, pages 2658 - 2663, XP002169469, ISSN: 0890-9369 *
FUCHS SERGE Y ET AL: "MEKK1/JNK signaling stabilizes and activates p53.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 95, no. 18, Sept. 1, 1998, pages 10541 - 10546, XP002169473, ISSN: 0027-8424 *
POTAPOVA OLGA ET AL: "c-Jun N-terminal kinase is essential for growth of human T98G glioblastoma cells.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 32, 11 August 2000 (2000-08-11), pages 24767 - 24775, XP002169476, ISSN: 0021-9258 *
POTAPOVA OLGA ET AL: "Inhibition of c-Jun N-Terminal kinase 2 expression suppresses growth and induces apoptosis of human tumor cells in a p53-dependent manner.", MOLECULAR AND CELLULAR BIOLOGY., vol. 20, no. 5, March 2000 (2000-03-01), pages 1713 - 1722, XP002169475, ISSN: 0270-7306 *
SCHREIBER MARTIN ET AL: "Control of cell cycle progression by c-Jun is p53 dependent.", GENES & DEVELOPMENT, vol. 13, no. 5, 1 March 1999 (1999-03-01), pages 607 - 619, XP002169474, ISSN: 0890-9369 *
XU XIAOXING S ET AL: "A role for c-Raf kinase and Ha-Ras in cytokine-mediated induction of cell adhesion molecules.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 50, 11 December 1998 (1998-12-11), pages 33230 - 33238, XP002169472, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2001034792A2 (en) 2001-05-17
AU1480801A (en) 2001-06-06

Similar Documents

Publication Publication Date Title
WO2000028090A3 (en) Diagnostic assay for cancer
PL344337A1 (en) Biodegradable sustained-release alginate gels
WO2003008583A3 (en) Novel compositions and methods for cancer
MXPA03003151A (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer.
AU2002219782A1 (en) Diindolylmethane and c-substituted diindolylmethane compositions and methods for the treatment of multiple cancers
ZA979550B (en) Method for the preparation of methylidene malonate nanoparticles, nanoparticles which optionally contain one or more biologically active molecules, and pharmaceutical compositions containing them.
MXPA04001524A (en) Rapamycin 29-enols.
WO2003048301A3 (en) Anti-hla-dr antibodies and the methods of using thereof
MXPA03008710A (en) Compositions and methods of zearalenone detoxification.
ZA993364B (en) Novel 4-phenylpiperidines for the treatment of pruritic dermatoses.
MY122278A (en) 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
MXPA04004939A (en) 3-alkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and 3,3'-dialkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and processes for making them.
WO2001017543A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
WO2001036685A3 (en) Differential gene expression in cancer
AU8661201A (en) Method, system and shoe enabling the determination of fit from outside of the shoe
MXPA03002323A (en) Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators.
EP2261256A3 (en) Methods of inhibiting metastasis
WO2003057146A3 (en) Novel compositions and methods for cancer
WO2002030941A3 (en) Topoisomerase inhibitors
WO2002036578A3 (en) Triazine derivatives as lpaat-b inhibitors and uses thereof
MXPA03001536A (en) Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same.
WO2000032765A3 (en) Ribozyme therapy for the treatment and/or prevention of restenosis
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
WO2004045545A3 (en) Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression
WO2002024867A3 (en) Novel compositions and methods for lymphoma and leukemia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase